echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > The Shanghai Public Health Clinical Center initiated the study of anti-PD-L1 antibody ASC22 (envolimumab) combined with Chidamide to achieve functional cure in HIV-infected patients

    The Shanghai Public Health Clinical Center initiated the study of anti-PD-L1 antibody ASC22 (envolimumab) combined with Chidamide to achieve functional cure in HIV-infected patients

    • Last Update: 2022-03-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com